secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001493152-24-019358
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics Q1 net loss $7.2M, cash $1.4M after $6.1M offering
-------------------------------------------------------------------------

- Net loss $7.2M ($0.20/share) vs $6.5M ($0.75/share) Q1 2023; R&D $2.7M, G&A $4.0M.
- Cash & restricted cash $1.4M at Mar 31, 2024, down from $2.1M at Dec 31, 2023.
- Closed public offering of 15.2M shares/warrants, gross proceeds $6.1M.
- Will present three posters at ASCO 2024 including Phase 1 update for CLD-101 in recurrent high-grade glioma.
- CEO states focus on raising additional capital and cost cutting; Phase 1 initiation with Northwestern expected Q3 2024 subject to capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315224019358/0001493152-24-019358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315224019358/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer